| 000 | 01427 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250514155828.0 | ||
| 264 | 0 | _c20040115 | |
| 008 | 200401s 0 0 eng d | ||
| 022 | _a0301-1526 | ||
| 024 | 7 |
_a10.1024/0301-1526.32.3.145 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKuss, M | |
| 245 | 0 | 0 |
_aHemostatic and fibrinolytic effects of systemic prostaglandin E1 therapy in patients with peripheral arterial disease. _h[electronic resource] |
| 260 |
_bVASA. Zeitschrift fur Gefasskrankheiten _cAug 2003 |
||
| 300 |
_a145-8 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAlprostadil _xadministration & dosage |
| 650 | 0 | 4 |
_aArterial Occlusive Diseases _xblood |
| 650 | 0 | 4 |
_aBlood Coagulation Factors _xmetabolism |
| 650 | 0 | 4 | _aBlood Coagulation Tests |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFibrinolysis _xdrug effects |
| 650 | 0 | 4 |
_aFibrinolytic Agents _xadverse effects |
| 650 | 0 | 4 |
_aHemorrhage _xblood |
| 650 | 0 | 4 |
_aHemostasis _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfusions, Intravenous |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aRisk Assessment |
| 700 | 1 | _aHeidrich, H | |
| 700 | 1 | _aKoettgen, E | |
| 773 | 0 |
_tVASA. Zeitschrift fur Gefasskrankheiten _gvol. 32 _gno. 3 _gp. 145-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1024/0301-1526.32.3.145 _zAvailable from publisher's website |
| 999 |
_c14283911 _d14283911 |
||